drugset / Trial / NCT01137747

Carfilzomib in Patients With Relapsed Acute Myeloid or Acute Lymphoblastic Leukemia

NCT01137747

Phase 1 Completed 18 enrolled Washington University School of Medicine
Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study is to test escalating doses of carfilzomib in patients with relapsed acute myeloid and acute lymphoblastic leukemia.

Timeline

Start
2010-10
Primary completion
2014-08
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Carfilzomib Other / unclassified 36 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 45 mg/m2 Intravenous
Subject Carfilzomib Other / unclassified 56 mg/m2 Intravenous

Indications